SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Audentes Therapeutics, Inc. – BOLD

NEW YORK,– Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Audentes Therapeutics, Inc. (“Audentes” or the “Company”) (Nasdaq: BOLD) relating to the sale of the Company to Astellas Pharma Inc. Under the terms of the Agreement, Audentes shareholders will have the right to receive $60.00 in cash for each Audentes common stock owned. 

The investigation focuses on whether Audentes and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company’s by 1) failing to conduct a fair process and 2) whether and by how much this proposed transaction undervalues the Company.

Monteverde & Associates PC is a national class action securities and consumer litigation law firm that has recovered millions of dollars and is committed to protecting shareholders and consumers from corporate wrongdoing.  Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the legal team at the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field.  He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer.

If you own common stock in Audentes Therapeutics, Inc and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.